Eisai Clinical Trials

Phase II Study of E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma

E7389-E044-207

Study Overview

E7389
eribulin mesilate
NCT00413192, EU CTR 2005-004272-20
Jan 2007 - Jun 2012
Soft Tissue Sarcoma
Progression-free Survival (PFS)

  • Males and females (age 18 and over)

  • Completed

  • Phase 2

  • Belgium, Denmark, France, Germany, Poland See more

Results

CSR Synopsis

Download PDF

Lay Summary

No download available

Publication reference citation

Schöffski P, et al. Activity of eribulin mesylate in patients with soft-tissue sarcoma: A phase 2 study in four independent histological subtypes. The Lancet Oncology 2011 10;12(11):1045-1052. DOI: 10.1016/S1470-2045(11)70230-3

Data Sharing

ClinicalStudyDataRequest.com (CSDR) is a multi sponsor site through which qualified researchers who wish to access clinical trial data and associated information in order to conduct further research can submit their research proposal or enquiry.

Redacted documents are available upon request for this study.

Document type Availability
Protocol
SAP
Sample CRF
Full CSR